Arqule Inc (ARQL) 1.35 $ARQL
ArQule, Inc. to Present at Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 7:15AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:00 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
ARQL: 1.35 (+0.04)
Investors look to Lighten Up on Shares of Arqule, Shares Down 6.6% (ARQL)
Comtex SmarTrend(R) - Tue Jan 06, 11:36AM CST
Arqule (NASDAQ:ARQL) is one of today's worst performing low-priced stocks, down 6.6% to $1.14 on 1.0x average daily volume. Arqule has traded 434,000 shares thus far today, vs. average volume of 425,000 shares per day. The stock has underperformed the Dow (-6.6% to the Dow's -1.1%) and underperformed the S&P 500 (-6.6% to the S&P's -1.1%) during today's trading.
ARQL: 1.35 (+0.04)
Strength Seen in ArQule (ARQL): Stock Moves 7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:46AM CST
ArQule (ARQL) was a big mover last session, with shares rising just over 7% on the day.
ARQL: 1.35 (+0.04), CEMP: 27.68 (+1.25)
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:35PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), ARIA: 7.35 (+0.45), BIOD: 1.38 (-0.14)
Minerva Neurosciences (NERV) Rises: Stock Adds 10.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 7:44AM CST
Minerva Neurosciences (NERV) was a big mover last session, as the company saw its shares rise nearly 11%
NERV: 4.68 (+0.09), ARQL: 1.35 (+0.04)
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BRLI: 34.63 (+0.06), AXGN: 3.45 (+0.02), AZPN: 38.40 (+0.79), ARQL: 1.35 (+0.04), ADUS: 21.57 (+0.18)
Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 18.79 (unch), ARQL: 1.35 (+0.04)
PTC Therapeutics, Inc. (PTCT) in Focus: Stock Gains 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:32AM CST
PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise more than 5% on the day.
LGI: 16.21 (+0.01), ARQL: 1.35 (+0.04), PTCT: 53.37 (-0.74), IG: 10.57 (-0.12)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
DXLG: 5.16 (+0.07), GPN: 91.86 (-0.32), AXGN: 3.45 (+0.02), ARQL: 1.35 (+0.04), ELNK: 4.54 (+0.05)
Liquidity Services, Inc. to Conduct Auction of High-Value Life Sciences Equipment
PR Newswire - Tue Dec 09, 7:30AM CST
Liquidity Services, Inc. (NASDAQ:LQDT) a global solution provider in the reverse supply chain with the world's largest marketplace for business surplus, is conducting an online auction for surplus equipment including biotech, research and development, and lab equipment not utilized in ArQule, Inc's (NASDAQ:ARQL) Woburn, MA facility. The assets consist of high-value, late-model analytical equipment including high performance liquid chromatograph systems, imaging systems, mass spectrometers, NMR systems, pharmaceutical processing equipment and general lab equipment.
LQDT: 9.52 (+0.09), ARQL: 1.35 (+0.04)
ChemoCentryx Drug Gets Orphan Designation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 5:07PM CST
Positive news flowed in for ChemoCentryx, Inc., (CCXI) when it announced that the European Commission has granted orphan medicinal product designation to its pipeline candidate CCX168.
VRX: 167.00 (-0.50), ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04)
Stock to Watch: Arqule Up 10.5% (ARQL)
Comtex SmarTrend(R) - Thu Dec 04, 12:42PM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 10.5% to $1.37 on 1.0x average daily volume. Arqule has traded 352,000 shares thus far today, vs. average volume of 342,000 shares per day. The stock has outperformed the Dow (10.5% to the Dow's 0.0%) and outperformed the S&P 500 (10.5% to the S&P's 0.0%) during today's trading.
ARQL: 1.35 (+0.04)
Can the Uptrend Continue for ArQule (ARQL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 5:36AM CST
Can the Uptrend Continue for ArQule (ARQL)?
ARQL: 1.35 (+0.04)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 21.99 (-0.19), ARQL: 1.35 (+0.04), CDXS: 3.42 (+0.07)
ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 57.78 (-0.91), ARQL: 1.35 (+0.04), BIOD: 1.38 (-0.14)
Traders Get Bullish on Shares of Arqule, Shares Up 6.0% (ARQL)
Comtex SmarTrend(R) - Mon Nov 17, 12:01PM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 6.0% to $1.24 on 2.3x average daily volume. Thus far today, Arqule has traded 663,000 shares, vs. average volume of 290,000 shares per day. The stock has outperformed the Dow (6.0% to the Dow's -0.1%) and outperformed the S&P 500 (6.0% to the S&P's -0.2%) during today's trading.
ARQL: 1.35 (+0.04)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 169.69 (+6.89), ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), RDY: 54.15 (-0.01)
ArQule Announces Data Presentations with Pipeline Products to Be Featured at 26th EORTC-NCI-AACR Symposium
Business Wire - Thu Nov 13, 7:00AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that eight presentations of clinical and pre-clinical data on three early clinical-stage product candidates will take place during the 26th EORTC-NCI-AACR Symposium to be held November 18-21, 2014 in Barcelona, Spain.
ARQL: 1.35 (+0.04)
ArQule, Inc. to Present at Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 7:15AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:00 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
ARQL: 1.35 (+0.04)
Investors look to Lighten Up on Shares of Arqule, Shares Down 6.6% (ARQL)
Comtex SmarTrend(R) - Tue Jan 06, 11:36AM CST
Arqule (NASDAQ:ARQL) is one of today's worst performing low-priced stocks, down 6.6% to $1.14 on 1.0x average daily volume. Arqule has traded 434,000 shares thus far today, vs. average volume of 425,000 shares per day. The stock has underperformed the Dow (-6.6% to the Dow's -1.1%) and underperformed the S&P 500 (-6.6% to the S&P's -1.1%) during today's trading.
ARQL: 1.35 (+0.04)
Strength Seen in ArQule (ARQL): Stock Moves 7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:46AM CST
ArQule (ARQL) was a big mover last session, with shares rising just over 7% on the day.
ARQL: 1.35 (+0.04), CEMP: 27.68 (+1.25)
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:35PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), ARIA: 7.35 (+0.45), BIOD: 1.38 (-0.14)
Minerva Neurosciences (NERV) Rises: Stock Adds 10.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 7:44AM CST
Minerva Neurosciences (NERV) was a big mover last session, as the company saw its shares rise nearly 11%
NERV: 4.68 (+0.09), ARQL: 1.35 (+0.04)
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BRLI: 34.63 (+0.06), AXGN: 3.45 (+0.02), AZPN: 38.40 (+0.79), ARQL: 1.35 (+0.04), ADUS: 21.57 (+0.18)
Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 18.79 (unch), ARQL: 1.35 (+0.04)
PTC Therapeutics, Inc. (PTCT) in Focus: Stock Gains 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:32AM CST
PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise more than 5% on the day.
LGI: 16.21 (+0.01), ARQL: 1.35 (+0.04), PTCT: 53.37 (-0.74), IG: 10.57 (-0.12)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
DXLG: 5.16 (+0.07), GPN: 91.86 (-0.32), AXGN: 3.45 (+0.02), ARQL: 1.35 (+0.04), ELNK: 4.54 (+0.05)
Liquidity Services, Inc. to Conduct Auction of High-Value Life Sciences Equipment
PR Newswire - Tue Dec 09, 7:30AM CST
Liquidity Services, Inc. (NASDAQ:LQDT) a global solution provider in the reverse supply chain with the world's largest marketplace for business surplus, is conducting an online auction for surplus equipment including biotech, research and development, and lab equipment not utilized in ArQule, Inc's (NASDAQ:ARQL) Woburn, MA facility. The assets consist of high-value, late-model analytical equipment including high performance liquid chromatograph systems, imaging systems, mass spectrometers, NMR systems, pharmaceutical processing equipment and general lab equipment.
LQDT: 9.52 (+0.09), ARQL: 1.35 (+0.04)
ChemoCentryx Drug Gets Orphan Designation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 5:07PM CST
Positive news flowed in for ChemoCentryx, Inc., (CCXI) when it announced that the European Commission has granted orphan medicinal product designation to its pipeline candidate CCX168.
VRX: 167.00 (-0.50), ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04)
Stock to Watch: Arqule Up 10.5% (ARQL)
Comtex SmarTrend(R) - Thu Dec 04, 12:42PM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 10.5% to $1.37 on 1.0x average daily volume. Arqule has traded 352,000 shares thus far today, vs. average volume of 342,000 shares per day. The stock has outperformed the Dow (10.5% to the Dow's 0.0%) and outperformed the S&P 500 (10.5% to the S&P's 0.0%) during today's trading.
ARQL: 1.35 (+0.04)
Can the Uptrend Continue for ArQule (ARQL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 5:36AM CST
Can the Uptrend Continue for ArQule (ARQL)?
ARQL: 1.35 (+0.04)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 21.99 (-0.19), ARQL: 1.35 (+0.04), CDXS: 3.42 (+0.07)
ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 57.78 (-0.91), ARQL: 1.35 (+0.04), BIOD: 1.38 (-0.14)
Traders Get Bullish on Shares of Arqule, Shares Up 6.0% (ARQL)
Comtex SmarTrend(R) - Mon Nov 17, 12:01PM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 6.0% to $1.24 on 2.3x average daily volume. Thus far today, Arqule has traded 663,000 shares, vs. average volume of 290,000 shares per day. The stock has outperformed the Dow (6.0% to the Dow's -0.1%) and outperformed the S&P 500 (6.0% to the S&P's -0.2%) during today's trading.
ARQL: 1.35 (+0.04)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 169.69 (+6.89), ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), RDY: 54.15 (-0.01)
ArQule Announces Data Presentations with Pipeline Products to Be Featured at 26th EORTC-NCI-AACR Symposium
Business Wire - Thu Nov 13, 7:00AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that eight presentations of clinical and pre-clinical data on three early clinical-stage product candidates will take place during the 26th EORTC-NCI-AACR Symposium to be held November 18-21, 2014 in Barcelona, Spain.
ARQL: 1.35 (+0.04)
